Orphan Drug Development, LAL Deficiency, Synageva BioPharma Company

Rating: 0 - 0 votes

Company Logo

Company Name

Company Contact

Website Analysis

• Home Page Analysis
• Web Presence
• Home Page Speed

Domain Whois

WHOIS information for trimeris.com

Powered by who.is

Page Type

This page is about a company.

Description

pulled from site's meta description

Synageva was formed to concentrate on orphan drug treatments for rare diseases. Our lead program, SBC-102, is an enzyme replacement therapy for LAL Deficiency

---

This is an automatically generated AboutUs page for trimeris.com. Click the "Edit" button at the top of the page to make changes. Please read our Getting Started page if you need any help.

×

Edit Page Image

×

Select image...

• jpeg, png, or gif
• one megabyte or smaller
• will be resized to 270 pixels wide

Close Save changes

×

Edit Name

×

Name

Close Save changes

×

Edit Contact Information

×

Address

City

State

Country

Postal Code

Phone

Fax

Email

Close Save changes

×

Edit Page Type

×

Page Type
Business / Organization Person Place Thing Other

Close Save changes

×

Map

×

×

Edit Page Rating

×

Your Rating

Close Save changes